Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound
Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantl...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bartolotta, Tommaso Vincenzo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2007 |
|---|
| Anmerkung: |
© Springer Science+Business Media, LLC 2007 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Abdominal radiology - [Boston, MA] : Springer US, 2016, 33(2007), 5 vom: 31. Aug., Seite 501-511 |
|---|---|
| Übergeordnetes Werk: |
volume:33 ; year:2007 ; number:5 ; day:31 ; month:08 ; pages:501-511 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00261-007-9294-1 |
|---|
| Katalog-ID: |
SPR003185079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR003185079 | ||
| 003 | DE-627 | ||
| 005 | 20230519155154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00261-007-9294-1 |2 doi | |
| 035 | |a (DE-627)SPR003185079 | ||
| 035 | |a (SPR)s00261-007-9294-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bartolotta, Tommaso Vincenzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC 2007 | ||
| 520 | |a Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. | ||
| 700 | 1 | |a Taibbi, Adele |4 aut | |
| 700 | 1 | |a Midiri, Massimo |4 aut | |
| 700 | 1 | |a De Maria, Marcello |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Abdominal radiology |d [Boston, MA] : Springer US, 2016 |g 33(2007), 5 vom: 31. Aug., Seite 501-511 |w (DE-627)847023133 |w (DE-600)2845742-0 |x 2366-0058 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2007 |g number:5 |g day:31 |g month:08 |g pages:501-511 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00261-007-9294-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_2113 | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2007 |e 5 |b 31 |c 08 |h 501-511 | ||
| author_variant |
t v b tv tvb a t at m m mm m m d mm mmd |
|---|---|
| matchkey_str |
article:23660058:2007----::eaoellracrepneoaifeunyuoaltocn |
| hierarchy_sort_str |
2007 |
| publishDate |
2007 |
| allfields |
10.1007/s00261-007-9294-1 doi (DE-627)SPR003185079 (SPR)s00261-007-9294-1-e DE-627 ger DE-627 rakwb eng Bartolotta, Tommaso Vincenzo verfasserin aut Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media, LLC 2007 Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. Taibbi, Adele aut Midiri, Massimo aut De Maria, Marcello aut Enthalten in Abdominal radiology [Boston, MA] : Springer US, 2016 33(2007), 5 vom: 31. Aug., Seite 501-511 (DE-627)847023133 (DE-600)2845742-0 2366-0058 nnns volume:33 year:2007 number:5 day:31 month:08 pages:501-511 https://dx.doi.org/10.1007/s00261-007-9294-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 AR 33 2007 5 31 08 501-511 |
| spelling |
10.1007/s00261-007-9294-1 doi (DE-627)SPR003185079 (SPR)s00261-007-9294-1-e DE-627 ger DE-627 rakwb eng Bartolotta, Tommaso Vincenzo verfasserin aut Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media, LLC 2007 Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. Taibbi, Adele aut Midiri, Massimo aut De Maria, Marcello aut Enthalten in Abdominal radiology [Boston, MA] : Springer US, 2016 33(2007), 5 vom: 31. Aug., Seite 501-511 (DE-627)847023133 (DE-600)2845742-0 2366-0058 nnns volume:33 year:2007 number:5 day:31 month:08 pages:501-511 https://dx.doi.org/10.1007/s00261-007-9294-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 AR 33 2007 5 31 08 501-511 |
| allfields_unstemmed |
10.1007/s00261-007-9294-1 doi (DE-627)SPR003185079 (SPR)s00261-007-9294-1-e DE-627 ger DE-627 rakwb eng Bartolotta, Tommaso Vincenzo verfasserin aut Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media, LLC 2007 Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. Taibbi, Adele aut Midiri, Massimo aut De Maria, Marcello aut Enthalten in Abdominal radiology [Boston, MA] : Springer US, 2016 33(2007), 5 vom: 31. Aug., Seite 501-511 (DE-627)847023133 (DE-600)2845742-0 2366-0058 nnns volume:33 year:2007 number:5 day:31 month:08 pages:501-511 https://dx.doi.org/10.1007/s00261-007-9294-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 AR 33 2007 5 31 08 501-511 |
| allfieldsGer |
10.1007/s00261-007-9294-1 doi (DE-627)SPR003185079 (SPR)s00261-007-9294-1-e DE-627 ger DE-627 rakwb eng Bartolotta, Tommaso Vincenzo verfasserin aut Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media, LLC 2007 Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. Taibbi, Adele aut Midiri, Massimo aut De Maria, Marcello aut Enthalten in Abdominal radiology [Boston, MA] : Springer US, 2016 33(2007), 5 vom: 31. Aug., Seite 501-511 (DE-627)847023133 (DE-600)2845742-0 2366-0058 nnns volume:33 year:2007 number:5 day:31 month:08 pages:501-511 https://dx.doi.org/10.1007/s00261-007-9294-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 AR 33 2007 5 31 08 501-511 |
| allfieldsSound |
10.1007/s00261-007-9294-1 doi (DE-627)SPR003185079 (SPR)s00261-007-9294-1-e DE-627 ger DE-627 rakwb eng Bartolotta, Tommaso Vincenzo verfasserin aut Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media, LLC 2007 Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. Taibbi, Adele aut Midiri, Massimo aut De Maria, Marcello aut Enthalten in Abdominal radiology [Boston, MA] : Springer US, 2016 33(2007), 5 vom: 31. Aug., Seite 501-511 (DE-627)847023133 (DE-600)2845742-0 2366-0058 nnns volume:33 year:2007 number:5 day:31 month:08 pages:501-511 https://dx.doi.org/10.1007/s00261-007-9294-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 AR 33 2007 5 31 08 501-511 |
| language |
English |
| source |
Enthalten in Abdominal radiology 33(2007), 5 vom: 31. Aug., Seite 501-511 volume:33 year:2007 number:5 day:31 month:08 pages:501-511 |
| sourceStr |
Enthalten in Abdominal radiology 33(2007), 5 vom: 31. Aug., Seite 501-511 volume:33 year:2007 number:5 day:31 month:08 pages:501-511 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Abdominal radiology |
| authorswithroles_txt_mv |
Bartolotta, Tommaso Vincenzo @@aut@@ Taibbi, Adele @@aut@@ Midiri, Massimo @@aut@@ De Maria, Marcello @@aut@@ |
| publishDateDaySort_date |
2007-08-31T00:00:00Z |
| hierarchy_top_id |
847023133 |
| id |
SPR003185079 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003185079</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519155154.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00261-007-9294-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003185079</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00261-007-9294-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bartolotta, Tommaso Vincenzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer Science+Business Media, LLC 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taibbi, Adele</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Midiri, Massimo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Maria, Marcello</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Abdominal radiology</subfield><subfield code="d">[Boston, MA] : Springer US, 2016</subfield><subfield code="g">33(2007), 5 vom: 31. Aug., Seite 501-511</subfield><subfield code="w">(DE-627)847023133</subfield><subfield code="w">(DE-600)2845742-0</subfield><subfield code="x">2366-0058</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:5</subfield><subfield code="g">day:31</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:501-511</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00261-007-9294-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2007</subfield><subfield code="e">5</subfield><subfield code="b">31</subfield><subfield code="c">08</subfield><subfield code="h">501-511</subfield></datafield></record></collection>
|
| author |
Bartolotta, Tommaso Vincenzo |
| spellingShingle |
Bartolotta, Tommaso Vincenzo Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| authorStr |
Bartolotta, Tommaso Vincenzo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)847023133 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2366-0058 |
| topic_title |
Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Abdominal radiology |
| hierarchy_parent_id |
847023133 |
| hierarchy_top_title |
Abdominal radiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)847023133 (DE-600)2845742-0 |
| title |
Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| ctrlnum |
(DE-627)SPR003185079 (SPR)s00261-007-9294-1-e |
| title_full |
Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| author_sort |
Bartolotta, Tommaso Vincenzo |
| journal |
Abdominal radiology |
| journalStr |
Abdominal radiology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2007 |
| contenttype_str_mv |
txt |
| container_start_page |
501 |
| author_browse |
Bartolotta, Tommaso Vincenzo Taibbi, Adele Midiri, Massimo De Maria, Marcello |
| container_volume |
33 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bartolotta, Tommaso Vincenzo |
| doi_str_mv |
10.1007/s00261-007-9294-1 |
| title_sort |
hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| title_auth |
Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| abstract |
Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. © Springer Science+Business Media, LLC 2007 |
| abstractGer |
Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. © Springer Science+Business Media, LLC 2007 |
| abstract_unstemmed |
Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement. © Springer Science+Business Media, LLC 2007 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_150 GBV_ILN_2113 |
| container_issue |
5 |
| title_short |
Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound |
| url |
https://dx.doi.org/10.1007/s00261-007-9294-1 |
| remote_bool |
true |
| author2 |
Taibbi, Adele Midiri, Massimo De Maria, Marcello |
| author2Str |
Taibbi, Adele Midiri, Massimo De Maria, Marcello |
| ppnlink |
847023133 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00261-007-9294-1 |
| up_date |
2024-07-03T17:51:32.413Z |
| _version_ |
1803581225607102464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003185079</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519155154.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00261-007-9294-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003185079</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00261-007-9294-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bartolotta, Tommaso Vincenzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer Science+Business Media, LLC 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-scale US techniques, which are very sensitive to non-linear behavior of microbubbles, have been introduced. These features have opened new prospects in liver ultrasound and may have a great impact on daily practice, including cost-effective assessment of therapeutic response of percutaneous ablative therapies. Technical evolution of CEUS focusing on findings after RFA are illustrated. These latter are detailed, cross-referenced with the literature and discussed on the basis of our personal experience. Timing of CEUS posttreatment assessment among with advantages and limitations of CEUS are also described with a perspective on further technologic refinement.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taibbi, Adele</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Midiri, Massimo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Maria, Marcello</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Abdominal radiology</subfield><subfield code="d">[Boston, MA] : Springer US, 2016</subfield><subfield code="g">33(2007), 5 vom: 31. Aug., Seite 501-511</subfield><subfield code="w">(DE-627)847023133</subfield><subfield code="w">(DE-600)2845742-0</subfield><subfield code="x">2366-0058</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:5</subfield><subfield code="g">day:31</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:501-511</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00261-007-9294-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2007</subfield><subfield code="e">5</subfield><subfield code="b">31</subfield><subfield code="c">08</subfield><subfield code="h">501-511</subfield></datafield></record></collection>
|
| score |
7.400527 |